• Executive Summary o Market Overview • Market Landscape o Market ecosystem o Market characteristics o Value chain analysis • Market Sizing o Market definition o Market segment analysis o Market size 2020 o Market outlook: Forecast for 2020 - 2025 • Five Forces Analysis o Five forces summary o Bargaining power of buyers o Bargaining power of suppliers o Threat of new entrants o Threat of substitutes o Threat of rivalry o Market condition • Market Segmentation by Product o Market segments o Comparison by Product o Retinal disorder therapeutics - Market size and forecast 2020-2025 o Glaucoma therapeutics - Market size and forecast 2020-2025 o Dry eye disease therapeutics - Market size and forecast 2020-2025 o Eye infections and inflammation therapeutics - Market size and forecast 2020-2025 o Other therapeutics - Market size and forecast 2020-2025 o Market opportunity by Product • Customer Landscape • Geographic Landscape o Geographic segmentation o Geographic comparison o North America - Market size and forecast 2020-2025 o Europe - Market size and forecast 2020-2025 o Asia - Market size and forecast 2020-2025 o ROW - Market size and forecast 2020-2025 o Key leading countries o Market opportunity by geography o Market drivers o Market challenges o Market trends • Vendor Landscape o Vendor landscape o Landscape disruption o Competitive scenario • Vendor Analysis o Vendors covered o Market positioning of vendors o AbbVie Inc. o Aerie Pharmaceuticals Inc. o Bayer AG o F. Hoffmann-La Roche Ltd. o Novartis AG o Otsuka Holdings Co. Ltd. o Pfizer Inc. o Regeneron Pharmaceuticals Inc. o Santen Pharmaceutical Co. Ltd. o Teva Pharmaceutical Industries Ltd. • Appendix o Scope of the report o Currency conversion rates for US$ o Research methodology o List of abbreviations Exhibit • 1: Key Finding 1 • 2: Key Finding 2 • 3: Key Finding 3 • 4: Key Finding 5 • 5: Key Finding 6 • 6: Key Finding 7 • 7: Key Finding 8 • 8: Parent market • 9: Market characteristics • 10: Offerings of vendors included in the market definition • 11: Market segments • 12: Global - Market size and forecast 2020 - 2025 ($ billion) • 13: Global market: Year-over-year growth 2020 - 2025 (%) • 14: Five forces analysis 2020 & 2025 • 15: Bargaining power of buyers • 16: Bargaining power of suppliers • 17: Threat of new entrants • 18: Threat of substitutes • 19: Threat of rivalry • 20: Market condition - Five forces 2020 • 21: Product - Market share 2020-2025 (%) • 22: Comparison by Product • 23: Retinal disorder therapeutics - Market size and forecast 2020-2025 ($ billion) • 24: Retinal disorder therapeutics - Year-over-year growth 2020-2025 (%) • 25: Glaucoma therapeutics - Market size and forecast 2020-2025 ($ billion) • 26: Glaucoma therapeutics - Year-over-year growth 2020-2025 (%) • 27: Dry eye disease therapeutics - Market size and forecast 2020-2025 ($ billion) • 28: Dry eye disease therapeutics - Year-over-year growth 2020-2025 (%) • 29: Eye infections and inflammation therapeutics - Market size and forecast 2020-2025 ($ billion) • 30: Eye infections and inflammation therapeutics - Year-over-year growth 2020-2025 (%) • 31: Other therapeutics - Market size and forecast 2020-2025 ($ billion) • 32: Other therapeutics - Year-over-year growth 2020-2025 (%) • 33: Market opportunity by Product • 34: Customer landscape • 35: Market share by geography 2020-2025 (%) • 36: Geographic comparison • 37: North America - Market size and forecast 2020-2025 ($ billion) • 38: North America - Year-over-year growth 2020-2025 (%) • 39: Europe - Market size and forecast 2020-2025 ($ billion) • 40: Europe - Year-over-year growth 2020-2025 (%) • 41: Asia - Market size and forecast 2020-2025 ($ billion) • 42: Asia - Year-over-year growth 2020-2025 (%) • 43: ROW - Market size and forecast 2020-2025 ($ billion) • 44: ROW - Year-over-year growth 2020-2025 (%) • 45: Key leading countries • 46: Market opportunity by geography ($ billion) • 47: Impact of drivers and challenges • 48: Vendor landscape • 49: Landscape disruption • 50: Industry risks • 51: Vendors covered • 52: Market positioning of vendors • 53: AbbVie Inc. - Overview • 54: AbbVie Inc. - Business segments • 55: AbbVie Inc. - Key offerings • 56: AbbVie Inc. - Key customers • 57: AbbVie Inc. - Segment focus • 58: Aerie Pharmaceuticals Inc. - Overview • 59: Aerie Pharmaceuticals Inc. - Business segments • 60: Aerie Pharmaceuticals Inc. - Key offerings • 61: Aerie Pharmaceuticals Inc. - Key customers • 62: Aerie Pharmaceuticals Inc. - Segment focus • 63: Bayer AG - Overview • 64: Bayer AG - Business segments • 65: Bayer AG - Key offerings • 66: Bayer AG - Key customers • 67: Bayer AG - Segment focus • 68: F. Hoffmann-La Roche Ltd. - Overview • 69: F. Hoffmann-La Roche Ltd. - Business segments • 70: F. Hoffmann-La Roche Ltd. - Key offerings • 71: F. Hoffmann-La Roche Ltd. - Key customers • 72: F. Hoffmann-La Roche Ltd. - Segment focus • 73: Novartis AG - Overview • 74: Novartis AG - Business segments • 75: Novartis AG - Key offerings • 76: Novartis AG - Key customers • 77: Novartis AG - Segment focus • 78: Otsuka Holdings Co. Ltd. - Overview • 79: Otsuka Holdings Co. Ltd. - Business segments • 80: Otsuka Holdings Co. Ltd. - Key offerings • 81: Otsuka Holdings Co. Ltd. - Key customers • 82: Otsuka Holdings Co. Ltd. - Segment focus • 83: Pfizer Inc. - Overview • 84: Pfizer Inc. - Business segments • 85: Pfizer Inc. - Key offerings • 86: Pfizer Inc. - Key customers • 87: Pfizer Inc. - Segment focus • 88: Regeneron Pharmaceuticals Inc. - Overview • 89: Regeneron Pharmaceuticals Inc. - Business segments • 90: Regeneron Pharmaceuticals Inc. - Key offerings • 91: Regeneron Pharmaceuticals Inc. - Key customers • 92: Regeneron Pharmaceuticals Inc. - Segment focus • 93: Santen Pharmaceutical Co. Ltd. - Overview • 94: Santen Pharmaceutical Co. Ltd. - Business segments • 95: Santen Pharmaceutical Co. Ltd. - Key offerings • 96: Santen Pharmaceutical Co. Ltd. - Key customers • 97: Santen Pharmaceutical Co. Ltd. - Segment focus • 98: Teva Pharmaceutical Industries Ltd. - Overview • 99: Teva Pharmaceutical Industries Ltd. - Business segments • 100: Teva Pharmaceutical Industries Ltd. - Key offerings • 101: Teva Pharmaceutical Industries Ltd. - Key customers • 102: Teva Pharmaceutical Industries Ltd. - Segment focus • 103: Currency conversion rates for US$ • 104: Research Methodology • 105: Validation techniques employed for market sizing • 106: Information sources • 107: List of abbreviations

AbbVie Inc., Aerie Pharmaceuticals Inc., Bayer AG, F. Hoffmann-La Roche Ltd., Novartis AG, Otsuka Holdings Co. Ltd., Pfizer Inc., Regeneron Pharmaceuticals Inc., Santen Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd.